Renaissance Technologies LLC Boosts Stock Position in Insulet Corporation $PODD

Renaissance Technologies LLC boosted its holdings in shares of Insulet Corporation (NASDAQ:PODD) by 40.5% in the first quarter, Holdings Channel.com reports. The fund owned 426,003 shares of the medical instruments supplier’s stock after acquiring an additional 122,720 shares during the quarter. Renaissance Technologies LLC’s holdings in Insulet were worth $89,392,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of PODD. Larson Financial Group LLC lifted its position in shares of Insulet by 114.6% during the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. bought a new position in shares of Insulet in the fourth quarter worth about $26,000. Elyxium Wealth LLC bought a new position in shares of Insulet in the fourth quarter worth about $28,000. DV Equities LLC purchased a new position in Insulet in the 4th quarter worth about $28,000. Finally, MV Capital Management Inc. purchased a new position in Insulet in the 4th quarter worth about $29,000.

More Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: No meaningful positive company-specific catalysts were reported in the latest batch of news.
• Neutral Sentiment: Short-interest data showed 0 shares reported short as of July 24, with a 0.0-day days-to-cover ratio, offering little actionable insight from that update.
• Negative Sentiment: Multiple law firms, including Rosen, Schall, Glancy Prongay, Pomerantz, Bernstein Liebhard, Faruqi & Faruqi, and others, announced or promoted securities class actions against Insulet, which can weigh on investor confidence. Article link
• Negative Sentiment: The lawsuits allege Insulet made misleading statements about manufacturing quality and safety issues, including problems at its Acton facility and flawed pods, suggesting potential reputational and legal overhang for the stock. Article link

Insulet Stock Up 3.1%

NASDAQ:PODD opened at $163.26 on Friday. Insulet Corporation has a 1-year low of $138.79 and a 1-year high of $354.88. The company has a 50-day moving average of $154.09 and a 200 day moving average of $202.61. The firm has a market cap of $11.31 billion, a PE ratio of 37.97, a price-to-earnings-growth ratio of 1.14 and a beta of 1.11. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81.

Insulet (NASDAQ:PODD) last issued its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.19 by $0.23. The company had revenue of $761.70 million for the quarter, compared to analysts’ expectations of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The firm’s quarterly revenue was up 33.9% on a year-over-year basis. During the same period in the prior year, the business earned $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, research analysts anticipate that Insulet Corporation will post 6.45 EPS for the current fiscal year.

Analysts Set New Price Targets

PODD has been the subject of several research reports. Wall Street Zen cut shares of Insulet from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 27th. Benchmark reaffirmed a “buy” rating on shares of Insulet in a research report on Wednesday, May 27th. Canaccord Genuity Group decreased their price target on shares of Insulet from $435.00 to $249.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Weiss Ratings lowered Insulet from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, June 24th. Finally, Jefferies Financial Group dropped their price objective on Insulet from $400.00 to $360.00 in a research note on Thursday, May 7th. Twenty-two research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Insulet has an average rating of “Moderate Buy” and an average target price of $235.25.

Insider Buying and Selling at Insulet

In other Insulet news, Director Timothy C. Stonesifer acquired 2,790 shares of the company’s stock in a transaction dated Wednesday, June 3rd. The shares were purchased at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the purchase, the director owned 9,041 shares in the company, valued at approximately $1,297,473.91. This trade represents a 44.63% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 0.36% of the company’s stock.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.